{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:10:19Z","timestamp":1790763019492,"version":"4.1.0"},"reference-count":121,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,16]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Biological agents cross the placenta, resulting in detectable blood levels in the neonate. Neonatal vaccinations are essential to prevent serious infections.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To review the effectiveness and safety of vaccines in children exposed to biological drugs in utero and\/or those whose mothers received biological agents during lactation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic bibliographic search was performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Infants exposed in utero to anti-tumour necrosis factor drugs [anti-TNFs], vedolizumab or ustekinumab mount adequate serological responses to vaccines. No relevant adverse events for non-live inactivated vaccines have been reported in newborns exposed in utero to biologics. Studies assessing the safety of live-attenuated vaccines administered to infants exposed to biologics in utero have not observed, in general, serious adverse events. However, although no severe complications have been reported with rotavirus live vaccination, several fatal disseminated tuberculosis infections after administration of the BCG live vaccine in infants exposed to anti-TNFs in utero have been reported. Infliximab, adalimumab, and probably also vedolizumab and ustekinumab treatments are considered compatible with breastfeeding, although minuscule amounts of these biologics have been detected in breast milk of treated nursing mothers. Based on the literature available, the benefits from breastfeeding while receiving infliximab [or any other anti-TNF] and at the same time adhering to national infant immunization programmes probably outweigh any hypothetical risk for the infant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Vaccines appear to be effective in infants exposed to biologics in utero. Inactivated vaccines are probably safe, whereas live-attenuated vaccines should be avoided while the children have detectable levels of biological drugs. Vaccines [non-live and live] are probably safe in children breastfed by mothers treated with biologics.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjad005","type":"journal-article","created":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T12:26:07Z","timestamp":1673871967000},"page":"995-1009","source":"Crossref","is-referenced-by-count":26,"title":["Vaccines in Children Exposed to Biological Agents<i>In Utero<\/i>and\/or During Breastfeeding: Are They Effective and Safe?"],"prefix":"10.1093","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2090-3445","authenticated-orcid":false,"given":"Javier P","family":"Gisbert","sequence":"first","affiliation":[{"name":"Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigaci\u00f3n Sanitaria Princesa (IIS-Princesa), Universidad Aut\u00f3noma de Madrid (UAM), Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD) , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9275-4242","authenticated-orcid":false,"given":"Mar\u00eda","family":"Chaparro","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigaci\u00f3n Sanitaria Princesa (IIS-Princesa), Universidad Aut\u00f3noma de Madrid (UAM), Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD) , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,1,18]]},"reference":[{"key":"2023061613183036000_CIT0001","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/ajg.2013.171","article-title":"Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease","volume":"108","author":"Gisbert","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"2023061613183036000_CIT0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjac115","article-title":"European Crohn\u2019s and Colitis Guidelines on Sexuality, Fertility, Pregnancy, and Lactation","volume":"17","author":"Torres","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2023061613183036000_CIT0003","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/ajg.2010.464","article-title":"The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn\u2019s and Colitis Organisation: pregnancy and pediatrics","volume":"106","author":"Mahadevan","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"2023061613183036000_CIT0004","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/ecco-jcc\/jju006","article-title":"The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease","volume":"9","author":"van der Woude","year":"2015","journal-title":"J Crohns Colitis"},{"key":"2023061613183036000_CIT0005","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2015.12.003","article-title":"The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy","volume":"150","author":"Nguyen","year":"2016","journal-title":"Gastroenterology"},{"key":"2023061613183036000_CIT0006","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/ecco-jcc\/jjz195","article-title":"Predictors of primary response to biologic treatment [anti-TNF, vedolizumab, and ustekinumab] in patients with inflammatory bowel disease: from basic science to clinical practice","volume":"14","author":"Gisbert","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2023061613183036000_CIT0007","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s40265-020-01346-4","article-title":"Safety of new biologics (vedolizumab and ustekinumab) and small molecules (tofacitinib) during pregnancy: a review","volume":"80","author":"Gisbert","year":"2020","journal-title":"Drugs"},{"key":"2023061613183036000_CIT0008","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s40265-019-01141-w","article-title":"A pharmacological approach to managing inflammatory bowel disease during conception, pregnancy and breastfeeding: biologic and oral small molecule therapy","volume":"79","author":"Picardo","year":"2019","journal-title":"Drugs"},{"key":"2023061613183036000_CIT0009","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/j.gastro.2016.04.002","article-title":"Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection","volume":"151","author":"Julsgaard","year":"2016","journal-title":"Gastroenterology"},{"key":"2023061613183036000_CIT0010","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.cgh.2007.02.035","article-title":"Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease","volume":"5","author":"Mamula","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023061613183036000_CIT0011","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/ibd.21800","article-title":"Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study","volume":"18","author":"Fiorino","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"2023061613183036000_CIT0012","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.crohns.2012.05.011","article-title":"Immune response to influenza A\/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-alpha agents: effects of combined therapy with immunosuppressants","volume":"7","author":"Andrisani","year":"2013","journal-title":"J Crohns Colitis"},{"key":"2023061613183036000_CIT0013","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.crohns.2013.09.022","article-title":"Patients with Crohn\u2019s disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine","volume":"8","author":"Lee","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2023061613183036000_CIT0014","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1097\/MIB.0000000000000448","article-title":"Combined immunosuppression impairs immunogenicity to tetanus and pertussis vaccination among patients with inflammatory bowel disease","volume":"21","author":"Dezfoli","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"2023061613183036000_CIT0015","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.jaci.2021.07.005","article-title":"Safety of anti-TNF agents in pregnancy","volume":"148","author":"De Felice","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2023061613183036000_CIT0016","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/17474124.2021.1876562","article-title":"Biologics and pregnancy: a clinician\u2019s guide to the management of IBD in pregnant women","volume":"15","author":"Guerrero Vinsard","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2023061613183036000_CIT0017","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/ecco-jcc\/jjab052","article-title":"ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease","volume":"15","author":"Kucharzik","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2023061613183036000_CIT0018","article-title":"Recommendations of the Spanish Group on Crohn\u2019s Disease and Ulcerative Colitis on the importance, screening and vaccination in inflammatory bowel disease patients","author":"Ferreiro-Iglesias","year":"2022","journal-title":"Gastroenterol Hepatol"},{"key":"2023061613183036000_CIT0019","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1365-2036.2011.04617.x","article-title":"High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy","volume":"33","author":"Zelinkova","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"2023061613183036000_CIT0020","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cgh.2012.11.011","article-title":"Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease","volume":"11","author":"Mahadevan","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023061613183036000_CIT0021","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/ecco-jcc\/jjv118","article-title":"Treating inflammatory bowel disease in pregnancy: the issues we face today","volume":"9","author":"Damas","year":"2015","journal-title":"J Crohns Colitis"},{"key":"2023061613183036000_CIT0022","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1053\/j.gastro.2020.11.038","article-title":"Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease","volume":"160","author":"Mahadevan","year":"2021","journal-title":"Gastroenterology"},{"key":"2023061613183036000_CIT0023","doi-asserted-by":"crossref","first-page":"426","DOI":"10.23922\/jarc.2021-021","article-title":"Safety prediction of infants born to mothers with Crohn\u2019s disease treated with biological agents in the late gestation period","volume":"5","author":"Sako","year":"2021","journal-title":"J Anus Rectum Colon"},{"key":"2023061613183036000_CIT0024","doi-asserted-by":"crossref","first-page":"e28274","DOI":"10.1097\/MD.0000000000028274","article-title":"Management of inflammatory bowel disease and serum level of infliximab in newborn exposed to anti-TNF therapy during pregnancy: Case report and literature review","volume":"100","author":"de Arag\u00e3o","year":"2021","journal-title":"Medicine (Baltim)"},{"key":"2023061613183036000_CIT0025","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/ecco-jcc\/jjy058","article-title":"Anti-TNF levels in cord blood at birth are associated with anti-TNF type","volume":"12","author":"Kanis","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2023061613183036000_CIT0026","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/annrheumdis-2017-212196","article-title":"Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study","volume":"77","author":"Mariette","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2023061613183036000_CIT0027","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjac093","article-title":"Timing of live attenuated vaccination in infants exposed to infliximab or adalimumab in utero: A prospective cohort study in 107 children","author":"Liu","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2023061613183036000_CIT0028","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/ajg.2017.501","article-title":"Long-Term safety of in utero exposure to anti-TNFalpha drugs for the treatment of inflammatory bowel disease: results from the multicenter European TEDDY Study","volume":"113","author":"Chaparro","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"2023061613183036000_CIT0029","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.3389\/fimmu.2017.01123","article-title":"Immunological changes in blood of newborns exposed to anti-TNF-\u03b1 during pregnancy","volume":"8","author":"Esteve-Sol\u00e9","year":"2017","journal-title":"Front Immunol"},{"key":"2023061613183036000_CIT0030","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41424-018-0018-3","article-title":"Anti-TNF and thiopurine therapy in pregnant IBD patients does not significantly alter a panel of B-cell and T-cell subsets in 1-year-old infants","volume":"9","author":"Kattah","year":"2018","journal-title":"Clin Transl Gastroenterol"},{"key":"2023061613183036000_CIT0031","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.cgh.2006.07.018","article-title":"Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn","volume":"4","author":"Vasiliauskas","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023061613183036000_CIT0032","doi-asserted-by":"crossref","first-page":"935034","DOI":"10.3389\/fped.2022.935034","article-title":"Immune function in newborns with in-utero exposure to anti-TNFalpha therapy","volume":"10","author":"Weiss","year":"2022","journal-title":"Front Pediatr"},{"key":"2023061613183036000_CIT0033","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/ajg.2011.295","article-title":"Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab","volume":"107","author":"Moses","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"2023061613183036000_CIT0034","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1007\/s10620-015-3631-y","article-title":"Effect of immunosuppressive therapies for the treatment of inflammatory bowel disease on response to routine vaccinations: a meta-analysis","volume":"60","author":"Nguyen","year":"2015","journal-title":"Dig Dis Sci"},{"key":"2023061613183036000_CIT0035","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1038\/ajg.2012.79","article-title":"Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease","volume":"107","author":"Gisbert","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"2023061613183036000_CIT0036","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1016\/j.vaccine.2017.03.080","article-title":"Immune response to hepatitis B vaccination among people with inflammatory bowel diseases: A systematic review and meta-analysis","volume":"35","author":"Jiang","year":"2017","journal-title":"Vaccine"},{"key":"2023061613183036000_CIT0037","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.14309\/ajg.0000000000000289","article-title":"High immunogenicity of the pneumococcal conjugated vaccine in immunocompromised adults with inflammatory bowel disease","volume":"114","author":"Pittet","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"2023061613183036000_CIT0038","article-title":"Vaccines in children with inflammatory bowel disease: brief review","volume":"9","author":"Esposito","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"2023061613183036000_CIT0039","doi-asserted-by":"crossref","first-page":"7644","DOI":"10.3748\/wjg.v23.i42.7644","article-title":"Vaccinations in immunosuppressive-dependent pediatric inflammatory bowel disease","volume":"23","author":"Nguyen","year":"2017","journal-title":"World J Gastroenterol"},{"key":"2023061613183036000_CIT0040","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/MPG.0000000000002810","article-title":"Immune Response to Vaccination in children and young people with inflammatory bowel disease: a systematic review and meta-analysis","volume":"71","author":"Dembi\u0144ski","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2023061613183036000_CIT0041","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1093\/ecco-jcc\/jjy053","article-title":"Hepatitis B vaccination effective in children exposed to anti-tumour necrosis factor alpha in utero","volume":"12","author":"de Lima","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2023061613183036000_CIT0042","doi-asserted-by":"crossref","first-page":"237","DOI":"10.5217\/ir.2018.00071","article-title":"Influence of anti-tumor necrosis factor-alpha therapy to pregnant inflammatory bowel disease women and their children\u2019s immunity","volume":"17","author":"Lee","year":"2019","journal-title":"Intest Res"},{"key":"2023061613183036000_CIT0043","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/01.MIB.0000440984.86659.4f","article-title":"Impact of anti-tumor necrosis factor alpha antibodies administered to pregnant women with inflammatory bowel disease on long-term outcome of exposed children","volume":"20","author":"Bortlik","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"2023061613183036000_CIT0044","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1007\/s10620-015-3992-2","article-title":"The effect of maternal peripartum anti-TNF\u03b1 use on infant immune response","volume":"61","author":"Sheibani","year":"2016","journal-title":"Dig Dis Sci"},{"key":"2023061613183036000_CIT0045","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cgh.2017.08.041","article-title":"Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines","volume":"16","author":"Beaulieu","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023061613183036000_CIT0046","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/ibd\/izy294","article-title":"Safety of anti-TNF-alpha therapy during pregnancy on long-term outcome of exposed children: a controlled, multicenter observation","volume":"25","author":"Duricova","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2023061613183036000_CIT0047","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1097\/INF.0000000000003271","article-title":"Response to vaccination in infants exposed to antitumor necrosis factor alpha in utero","volume":"40","author":"Wieringa","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"2023061613183036000_CIT0048","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40780-022-00249-8","article-title":"Ustekinumab during pregnancy and lactation: drug levels in maternal serum, cord blood, breast milk, and infant serum","volume":"8","author":"Saito","year":"2022","journal-title":"J Pharm Health Care Sci"},{"key":"2023061613183036000_CIT0049","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/apt.16593","article-title":"Vedolizumab clearance in neonates, susceptibility to infections and developmental milestones: a prospective multicentre population-based cohort study","volume":"54","author":"Julsgaard","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2023061613183036000_CIT0050","doi-asserted-by":"crossref","first-page":"102676","DOI":"10.1016\/j.jaut.2021.102676","article-title":"Pregnancy and neonatal outcomes in women with immune mediated inflammatory diseases exposed to anti-tumor necrosis factor-\u03b1 during pregnancy: A systemic review and meta-analysis","volume":"122","author":"Barenbrug","year":"2021","journal-title":"J Autoimmun"},{"key":"2023061613183036000_CIT0051","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1080\/14760584.2021.1875825","article-title":"Immune response and safety of viral vaccines in children with autoimmune diseases on immune modulatory drug therapy","volume":"19","author":"Tse","year":"2020","journal-title":"Expert Rev Vaccines"},{"key":"2023061613183036000_CIT0052","first-page":"Cd004407","article-title":"Vaccines for measles, mumps, rubella, and varicella in children","volume":"11","author":"Di Pietrantonj","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"2023061613183036000_CIT0053","doi-asserted-by":"crossref","first-page":"8024","DOI":"10.1016\/j.vaccine.2020.10.028","article-title":"Varicella-zoster-virus vaccination of immunosuppressed children with inflammatory bowel disease or autoimmune hepatitis: A prospective observational study","volume":"38","author":"Seitel","year":"2020","journal-title":"Vaccine"},{"key":"2023061613183036000_CIT0054","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/MPG.0b013e3181bab351","article-title":"Varicella vaccination in children with inflammatory bowel disease receiving immunosuppressive therapy","volume":"50","author":"Lu","year":"2010","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2023061613183036000_CIT0055","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.crohns.2010.05.001","article-title":"Case Report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn\u2019s disease","volume":"4","author":"Cheent","year":"2010","journal-title":"J Crohns Colitis"},{"key":"2023061613183036000_CIT0056","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1111\/apt.15504","article-title":"Safety of first year vaccination in children born to mothers with inflammatory bowel disease and exposed in utero to anti-TNF\u03b1 agents: a French nationwide population-based cohort","volume":"50","author":"Luu","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2023061613183036000_CIT0057","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1093\/ecco-jcc\/jjaa099","article-title":"Safety and optimal timing of BCG vaccination in infants born to mothers receiving anti-TNF therapy for inflammatory bowel disease","volume":"14","author":"Park","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2023061613183036000_CIT0058","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/apt.15539","article-title":"Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study","volume":"51","author":"Moens","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2023061613183036000_CIT0059","first-page":"757","article-title":"Live vaccines in children exposed to biological agents for IBD in utero and\/or during breastfeeding: are they safe? Results from the DUMBO registry of GETECCU","volume":"10","author":"Chaparro","year":"2022","journal-title":"United Eur Gastroenterol J"},{"key":"2023061613183036000_CIT0060","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjac086","article-title":"Safety of ustekinumab and vedolizumab during pregnancy - pregnancy, neonatal and infant outcome: a prospective multicenter study","author":"Mitrova","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2023061613183036000_CIT0061","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1016\/j.vaccine.2022.03.041","article-title":"Efficacy, immunogenicity, and safety of available vaccines in children on biologics: A systematic review and meta-analysis","volume":"40","author":"Gertosio","year":"2022","journal-title":"Vaccine"},{"key":"2023061613183036000_CIT0062","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1136\/gutjnl-2019-319129","article-title":"Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life","volume":"70","author":"Kanis","year":"2021","journal-title":"Gut"},{"key":"2023061613183036000_CIT0063","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1093\/ibd\/izab266","article-title":"Safety of immunizations for the adult patient with inflammatory bowel disease-a systematic review and meta-analysis","volume":"28","author":"Desalermos","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"2023061613183036000_CIT0064","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/gutjnl-2014-307127","article-title":"Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results","volume":"64","author":"Wyant","year":"2015","journal-title":"Gut"},{"key":"2023061613183036000_CIT0065","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.dld.2021.05.015","article-title":"Vaccinations in patients with inflammatory bowel disease","volume":"53","author":"Macaluso","year":"2021","journal-title":"Dig Liver Dis"},{"key":"2023061613183036000_CIT0066","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1053\/j.gastro.2020.12.079","article-title":"Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)-Part 1: Live Vaccines","volume":"161","author":"Benchimol","year":"2021","journal-title":"Gastroenterology"},{"key":"2023061613183036000_CIT0067","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1093\/rheumatology\/keac141","article-title":"A systematic review of live vaccine outcomes in infants exposed to biologic disease modifying anti-rheumatic drugs in utero","volume":"61","author":"Goulden","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2023061613183036000_CIT0068","doi-asserted-by":"crossref","first-page":"17562848211018097","DOI":"10.1177\/17562848211018097","article-title":"The safety of drugs for inflammatory bowel disease during pregnancy and breastfeeding: the DUMBO registry study protocol of GETECCU","volume":"14","author":"Chaparro","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"key":"2023061613183036000_CIT0069"},{"key":"2023061613183036000_CIT0070"},{"key":"2023061613183036000_CIT0071","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.4161\/hv.24253","article-title":"A critical literature review of health economic evaluations of rotavirus vaccination","volume":"9","author":"Aballea","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"2023061613183036000_CIT0072","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1136\/flgastro-2020-101459","article-title":"Standards for the provision of antenatal care for patients with inflammatory bowel disease: guidance endorsed by the British Society of Gastroenterology and the British Maternal and Fetal Medicine Society","volume":"12","author":"Selinger","year":"2021","journal-title":"Frontline Gastroenterol"},{"key":"2023061613183036000_CIT0073","doi-asserted-by":"crossref","first-page":"11927","DOI":"10.3748\/wjg.v20.i33.11927","article-title":"Pregnant inflammatory bowel disease patients may require counselling regarding live vaccines in newborns","volume":"20","author":"Sekaran","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2023061613183036000_CIT0074","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1542\/peds.2004-2491","article-title":"Breastfeeding and the use of human milk","volume":"115","author":"Gartner","year":"2005","journal-title":"Pediatrics"},{"key":"2023061613183036000_CIT0075","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(15)01024-7","article-title":"Breastfeeding in the 21st century: epidemiology, mechanisms, and lifelong effect","volume":"387","author":"Victora","year":"2016","journal-title":"Lancet"},{"key":"2023061613183036000_CIT0076","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000516995","article-title":"The immune system in human milk: a historic perspective","volume":"77","author":"Goldman","year":"2021","journal-title":"Ann Nutr Metab"},{"key":"2023061613183036000_CIT0077","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/1-4020-3535-7_3","article-title":"Long term effects of breastfeeding on the infant and mother","volume":"569","author":"Schack-Nielsen","year":"2005","journal-title":"Adv Exp Med Biol"},{"key":"2023061613183036000_CIT0078","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4067\/S0370-41062017000100001","article-title":"[The benefits of breastfeeding and associated risks of replacement with baby formulas]","volume":"88","author":"Brahm","year":"2017","journal-title":"Rev Chil Pediatr"},{"key":"2023061613183036000_CIT0079","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1093\/ajcn\/80.5.1342","article-title":"Breastfeeding and risk of inflammatory bowel disease: a systematic review with meta-analysis","volume":"80","author":"Klement","year":"2004","journal-title":"Am J Clin Nutr"},{"key":"2023061613183036000_CIT0080","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jpeds.2009.03.017","article-title":"Systematic review: the role of breastfeeding in the development of pediatric inflammatory bowel disease","volume":"155","author":"Barclay","year":"2009","journal-title":"J Pediatr"},{"key":"2023061613183036000_CIT0081","doi-asserted-by":"crossref","first-page":"838S","DOI":"10.1093\/ajcn\/nqy371","article-title":"Infant milk-feeding practices and diagnosed celiac disease and inflammatory bowel disease in offspring: a systematic review","volume":"109","author":"Gungor","year":"2019","journal-title":"Am J Clin Nutr"},{"key":"2023061613183036000_CIT0082","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1572-0241.2005.40785.x","article-title":"The role of breastfeeding in postpartum disease activity in women with inflammatory bowel disease","volume":"100","author":"Kane","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"2023061613183036000_CIT0083","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/ajg.2009.362","article-title":"A population-based study of breastfeeding in inflammatory bowel disease: initiation, duration, and effect on disease in the postpartum period","volume":"104","author":"Moffatt","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"2023061613183036000_CIT0084","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3109\/00365521.2013.772229","article-title":"Fecundity, pregnancy outcomes, and breastfeeding in patients with inflammatory bowel disease: a large cohort survey","volume":"48","author":"Manosa","year":"2013","journal-title":"Scand J Gastroenterol"},{"key":"2023061613183036000_CIT0085","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.crohns.2012.08.012","article-title":"Maternal inflammatory bowel disease has short and long-term effects on the health of their offspring: a multicenter study in Israel","volume":"7","author":"Dotan","year":"2013","journal-title":"J Crohns Colitis"},{"key":"2023061613183036000_CIT0086","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1053\/j.gastro.2018.05.040","article-title":"Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel diseases and effects of breastfeeding on infections and development","volume":"155","author":"Matro","year":"2018","journal-title":"Gastroenterology"},{"key":"2023061613183036000_CIT0087","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/j.crohns.2012.09.010","article-title":"Inflammatory bowel disease and pregnancy: lack of knowledge is associated with negative views","volume":"7","author":"Selinger","year":"2013","journal-title":"J Crohns Colitis"},{"key":"2023061613183036000_CIT0088","doi-asserted-by":"crossref","first-page":"6193275","DOI":"10.1155\/2016\/6193275","article-title":"Management of inflammatory bowel disease during pregnancy and breastfeeding varies widely: a need for further education","volume":"2016","author":"Huang","year":"2016","journal-title":"Can J Gastroenterol Hepatol"},{"key":"2023061613183036000_CIT0089","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1002\/ibd.21522","article-title":"Self-reported adherence to medical treatment prior to and during pregnancy among women with ulcerative colitis","volume":"17","author":"Julsgaard","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"2023061613183036000_CIT0090","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.3748\/wjg.14.3085","article-title":"Is infliximab safe to use while breastfeeding?","volume":"14","author":"Stengel","year":"2008","journal-title":"World J Gastroenterol"},{"key":"2023061613183036000_CIT0091","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/MCG.0b013e31817f9367","article-title":"Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn\u2019s disease before and after delivery","volume":"43","author":"Kane","year":"2009","journal-title":"J Clin Gastroenterol"},{"key":"2023061613183036000_CIT0092","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.crohns.2011.05.006","article-title":"Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease","volume":"5","author":"Ben-Horin","year":"2011","journal-title":"J Crohns Colitis"},{"key":"2023061613183036000_CIT0093","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.cgh.2009.11.023","article-title":"Adalimumab level in breast milk of a nursing mother","volume":"8","author":"Ben-Horin","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023061613183036000_CIT0094","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.crohns.2013.09.003","article-title":"Infliximab concentrations in the milk of nursing mothers with inflammatory bowel disease","volume":"8","author":"Grosen","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2023061613183036000_CIT0095","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1097\/MCG.0b013e31825f2807","article-title":"Infliximab and adalimumab use during breastfeeding","volume":"46","author":"Fritzsche","year":"2012","journal-title":"J Clin Gastroenterol"},{"key":"2023061613183036000_CIT0096","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1053\/j.gastro.2018.12.022","article-title":"Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD Parenthood Project Working Group","volume":"156","author":"Mahadevan","year":"2019","journal-title":"Gastroenterology"},{"key":"2023061613183036000_CIT0097","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S2468-1253(22)00095-4","article-title":"Opacity over live vaccines in infants exposed to infliximab","volume":"7","author":"The Lancet Gastroenterology & Hepatology.","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2023061613183036000_CIT0098"},{"key":"2023061613183036000_CIT0099","doi-asserted-by":"crossref","first-page":"e001029","DOI":"10.1136\/bmjgast-2022-001029","article-title":"Live vaccinations for infants exposed to maternal infliximab in utero and via breast milk - the need for nuanced decision making","volume":"9","author":"Selinger","year":"2022","journal-title":"BMJ Open Gastroenterol"},{"key":"2023061613183036000_CIT0100","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.gastrohep.2014.12.003","article-title":"Vedolizumab in the treatment of Crohn\u2019s disease","volume":"38","author":"Gisbert","year":"2015","journal-title":"Gastroenterol Hepatol"},{"key":"2023061613183036000_CIT0101","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/apt.15027","article-title":"Letter: vedolizumab drug concentrations in neonates following intrauterine exposure","volume":"48","author":"Flanagan","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2023061613183036000_CIT0102","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/apt.14837","article-title":"Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease","volume":"48","author":"Julsgaard","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2023061613183036000_CIT0103","doi-asserted-by":"crossref","first-page":"17562848211032790","DOI":"10.1177\/17562848211032790","article-title":"Differences in the placental pharmacokinetics of vedolizumab and ustekinumab during pregnancy in women with inflammatory bowel disease: a prospective multicentre study","volume":"14","author":"Mitrova","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"key":"2023061613183036000_CIT0104","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s40262-017-0546-0","article-title":"A review of the clinical pharmacokinetics, pharmacodynamics, and immunogenicity of vedolizumab","volume":"56","author":"Rosario","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"2023061613183036000_CIT0105","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1111\/apt.16102","article-title":"Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure","volume":"52","author":"Flanagan","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2023061613183036000_CIT0106","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1053\/j.gastro.2016.05.061","article-title":"\u2018Just in time\u2019: when is it safe to administer live vaccines to infants exposed to anti-tumor necrosis factor agents in utero?","volume":"151","author":"Seow","year":"2016","journal-title":"Gastroenterology"},{"key":"2023061613183036000_CIT0107","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/1091581819864105","article-title":"Evaluation of the developmental toxicity of vedolizumab, an alpha4beta7 receptor antagonist, in rabbit and nonhuman primate","volume":"38","author":"Crawford","year":"2019","journal-title":"Int J Toxicol"},{"key":"2023061613183036000_CIT0108","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1053\/j.gastro.2017.08.067","article-title":"Vedolizumab concentrations in the breast milk of nursing mothers with inflammatory bowel disease","volume":"154","author":"Julsgaard","year":"2018","journal-title":"Gastroenterology"},{"key":"2023061613183036000_CIT0109","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/ecco-jcc\/jjx120","article-title":"Vedolizumab levels in breast milk of nursing mothers with inflammatory bowel disease","volume":"12","author":"Lahat","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2023061613183036000_CIT0110","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s40262-021-00985-4","article-title":"Vedolizumab concentrations in breast milk: results from a prospective, postmarketing, milk-only lactation study in nursing mothers with inflammatory bowel disease","volume":"60","author":"Sun","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"2023061613183036000_CIT0111","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.gastrohep.2017.08.006","article-title":"Ustekinumab to treat Crohn\u2019s disease","volume":"40","author":"Gisbert","year":"2017","journal-title":"Gastroenterol Hepatol"},{"key":"2023061613183036000_CIT0112","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"2023061613183036000_CIT0113","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"2023061613183036000_CIT0114","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/ecco-jcc\/jjx141","article-title":"Ustekinumab drug levels in maternal and cord blood in a woman with Crohn\u2019s disease treated until 33 weeks of gestation","volume":"12","author":"Rowan","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2023061613183036000_CIT0115","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/ecco-jcc\/jjy153","article-title":"Drug levels in the maternal serum, cord blood and breast milk of a ustekinumab-treated patient with Crohn\u2019s disease","volume":"13","author":"Klenske","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2023061613183036000_CIT0116","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/apt.16739","article-title":"Ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero","volume":"55","author":"Flanagan","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2023061613183036000_CIT0117","doi-asserted-by":"crossref","first-page":"101665","DOI":"10.1016\/j.bpg.2019.101665","article-title":"Effect of biologicals and JAK inhibitors during pregnancy on health-related outcomes in children of women with inflammatory bowel disease","volume":"44-45","author":"Wieringa","year":"2020","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"2023061613183036000_CIT0118","first-page":"1122","article-title":"Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use","volume":"12","author":"Brodmerkel","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"2023061613183036000_CIT0119","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1080\/21645515.2019.1574151","article-title":"High dose hepatitis B vaccine is not effective in patients using immunomodulatory drugs: a pilot study","volume":"15","author":"Haykir Solay","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"2023061613183036000_CIT0120"},{"key":"2023061613183036000_CIT0121","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/bdrb.20250","article-title":"Development in the cynomolgus macaque following administration of ustekinumab, a human anti-IL-12\/23p40 monoclonal antibody, during pregnancy and lactation","volume":"89","author":"Martin","year":"2010","journal-title":"Birth Defects Res B Dev Reprod Toxicol"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjad005\/49229313\/jjad005.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/17\/6\/995\/50627577\/jjad005.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/17\/6\/995\/50627577\/jjad005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T20:27:52Z","timestamp":1701721672000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/17\/6\/995\/6991317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,18]]},"references-count":121,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,1,18]]},"published-print":{"date-parts":[[2023,6,16]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad005","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6,1]]},"published":{"date-parts":[[2023,1,18]]}}}